Genprex, Inc.

NasdaqCM:GNPX Stock Report

Market Cap: US$8.2m

Genprex Management

Management criteria checks 3/4

Genprex's CEO is Ryan Confer, appointed in Sep 2016, has a tenure of 9.67 years. total yearly compensation is $728.87K, comprised of 65.9% salary and 34.1% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $10.90K. The average tenure of the management team and the board of directors is 4.5 years and 5.8 years respectively.

Key information

Ryan Confer

Chief executive officer

US$728.9k

Total compensation

CEO salary percentage65.86%
CEO tenure9.7yrs
CEO ownership0.1%
Management average tenure4.5yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Analysis Article • Aug 16

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 31

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Oct 12

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Aug 15

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Genprex (NASDAQ:GNPX) stock rose ~13% on Aug. 15 after the company said that the Safety Review Committee (SRC) approved continuation of a phase 1/2 trial of Reqorsa in combination with AstraZeneca's Tagrisso (osimertinib) to treat patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso. The SRC decision followed a review of the first group of patients in the phase 1 portion of the phase 1/2 study called Acclaim-1. "The SRC approval to advance Acclaim-1 to the higher dose in the second cohort of patients is an important milestone that further supports REQORSA's safety profile and brings us one step closer to bringing this potentially ground-breaking gene therapy approach to treating NSCLC to the patients who need it most," said Genprex Chief Medical Officer Mark Berger. The trial includes up to three sequential dose escalation groups, the company said in an Aug. 15 press release.
Analysis Article • Jun 14

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 09

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Nov 19

Genprex: Limited Clinical Data To Justify Risk

GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes. REQORSA—the company's main pipeline molecule—is targeting the Non-Small-Cell Lung Cancer Market. GNPX's share price is currently trading at around $2 after a quick fall from grace (from $15/share) following its IPO in early 2018. Although a low share price may be an attractive entry point, I believe the company has not yet produced any reliable proof of the clinical efficacy of its therapy. In this article, I will argue a neutral position on GNPX discussing the company's technology, market, and clinical data, to present a balanced view on both risk and opportunity.
Analysis Article • Oct 27

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 11

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO Compensation Analysis

How has Ryan Confer's remuneration changed compared to Genprex's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$17m

Dec 31 2025US$729kUS$480k

-US$16m

Sep 30 2025n/an/a

-US$17m

Jun 30 2025n/an/a

-US$18m

Mar 31 2025n/an/a

-US$19m

Dec 31 2024US$542kUS$462k

-US$21m

Sep 30 2024n/an/a

-US$23m

Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$28m

Dec 31 2023US$887kUS$426k

-US$31m

Sep 30 2023n/an/a

-US$31m

Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$1mUS$393k

-US$24m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$21m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$1mUS$345k

-US$21m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$1mUS$351k

-US$18m

Sep 30 2020n/an/a

-US$15m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$1mUS$300k

-US$11m

Compensation vs Market: Ryan's total compensation ($USD728.87K) is about average for companies of similar size in the US market ($USD647.34K).

Compensation vs Earnings: Ryan's compensation has increased whilst the company is unprofitable.

CEO

Ryan Confer (43 yo)

9.7yrs
Tenure
US$728,871
Compensation

Mr. Ryan M. Confer, M.S. has been the Chief Financial Officer of Genprex, Inc. since September 2016 and serves as its Chief Executive Officer, President and Director since May 08, 2024. Mr. Confer served a...

Leadership Team

NamePositionTenureCompensationOwnership
Ryan Confer
President9.7yrsUS$728.87k0.13%
$ 10.9k
Mark Berger
Chief Medical Officer4.7yrsUS$688.60k0.071%
$ 5.9k
David Schloss
Senior Vice President of Human Resources4.3yrsno datano data
Thomas Gallagher
Senior Vice President of Intellectual Property & Licensing5.7yrsno datano data
Suzanne Thornton-Jones
Senior Vice President of Regulatory Affairs & Quality2.8yrsno datano data
Celina Laney
Chief of Staffno datano datano data
Greg Jancarik
Senior Director & Corporate Controllerless than a yearno datano data
4.5yrs
Average Tenure

Experienced Management: GNPX's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ryan Confer
President2yrsUS$728.87k0.13%
$ 10.9k
Brent Longnecker
Independent Director6.2yrsUS$88.09k0.0015%
$ 124.0
James E. Rothman
Strategic Advisor to the Board of Directors13.8yrsno datano data
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datano datano data
Pasi Antero Janne
Member of Scientific & Medical Advisory Boardno datano datano data
George Peoples
Member of Clinical Advisory Board5.3yrsno datano data
Shu Kam Mok
Member of Scientific & Medical Advisory Boardno datano datano data
George Simon
Member of Scientific & Medical Advisory Boardno datano datano data
William Wilson
Independent Director6.2yrsUS$78.09k0.0015%
$ 124.0
Jose Antonio Toscano
Independent Non-Executive Chairman6.2yrsUS$103.09k0.0015%
$ 124.0
George Gittes
Member of Scientific Advisory Board5.5yrsno datano data
Michael Morse
Member of Clinical Advisory Board5.3yrsno datano data
5.8yrs
Average Tenure
65yo
Average Age

Experienced Board: GNPX's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/20 21:29
End of Day Share Price 2026/05/20 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genprex, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners